

Certificate of Analysis for NR-4526

Yersinia pestis F1-V Fusion Protein, Recombinant from Escherichia coli

Catalog No. NR-4526

Product Description: Yersinia pestis (Y. pestis) recombinant F1-V fusion protein was expressed in Escherichia coli and purified by conventional chromatography.

Lot1: FIN-0229 Manufacturing Date: 16JUN2006

TEST	SPECIFICATIONS	RESULTS
Appearance	Clear to slightly turbid, colorless liquid that may contain fine amorphous particles or aggregates	Clear, colorless liquid containing fine amorphous particles
Identification by Western Blot Antibody to F1-V protein	Major band at ~ 53 kDa	Major band at ~ 53 kDa
LDS-PAGE	Major band at ~ 53 kDa	Major band at ~ 53 kDa
Concentration by Spectrophotometer at OD ₂₈₀	0.3 mg/mL to 3.0 mg/mL	2.1 mg/mL
Potency Immunogenicity in mice with Protollin	Report result	Immune response in 100% of mice > 39 to 1357 fold higher than with unformulated F1-V ²
pH (post-vialing)	7.0 to 7.8	7.4
pl	Report result	~ 5.3
General Safety (21 CFR 610.11)	Meets requirements	Meets requirements
Endotoxin Content Limulus Amoebocyte Lysate assay, USP<85>	< 100 EU/mg protein	4.3 EU/mg protein
Sterility (21 CFR 610.12)	No growth	No growth

¹The cardboard storage box for Lot FIN-0229 may have been exposed to mold. All vials were disinfected prior to release.

Date: 29 JAN 2009 Signature: Signature on File

> Title: Technical Manager, BEI Authentication or designee

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by the contributor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

Biodefense and Emerging Infections Research Resources Repository P.O. Box 4137

800-359-7370

²Two doses of NPV containing 0.1 to 1 μg of Protollin and 0.3 to 10 μg F-1V, adjuvant:antigen ratios of 3.3:1 to 1:100 were used.